Healthy Volunteers (Meningococcal Infection)
Conditions
Brief summary
The primary objective of this study was to describe the safety profile of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate Vaccine and Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) Conjugate Vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.
Detailed description
Study duration per participant was approximately 16 months, which includes a safety follow-up contact at 6 months after the final vaccination.
Interventions
BIOLOGICALMeningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)
Pharmaceutical form: Liquid solution. Route of administration: Intramuscular
BIOLOGICALMeningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)
Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
BIOLOGICALDiphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine
Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
BIOLOGICALPneumococcal 13-valent Conjugate Vaccine
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
BIOLOGICALRotavirus Vaccine
Pharmaceutical form: Oral solution Route of administration: Oral
BIOLOGICALHepatitis B Vaccine
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
BIOLOGICALMeasles, Mumps, and Rubella Virus Vaccine
Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
BIOLOGICALVaricella Virus Vaccine
Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous
Sponsors
Sanofi Pasteur, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
A modified double blind design was used. With the exception of the personnel administering the vaccine, everyone involved in study (participants, care provider, investigator, safety outcomes assessor, Sponsor) was blinded.
Eligibility
Sex/Gender
ALL
Age
42 Days to 89 Days
Healthy volunteers
Yes
Inclusion criteria
* Aged \>= 42 to \<= 89 days on the day of the first study visit. * Healthy infants as determined by medical history, physical examination, and judgment of the investigator. * Informed consent form was signed and dated by the parent(s) or guardian (and by an independent witness if required by local regulations). * Participant and parent/guardian were able to attend all scheduled visits and complied with all trial procedures. * Infants who received the first dose of hepatitis B vaccine at least 28 days before the first study visit.
Exclusion criteria
* Participation at the time of study enrollment or in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure. * Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks before and / or following any trial vaccination except for influenza vaccination, which might be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines. * Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B serogroup-containing vaccine). * Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis A, measles, mumps, rubella, varicella; and Haemophilus influenzae type b, Streptococcus pneumoniae, and /or rotavirus infection or disease. * Receipt of more than 1 previous dose of hepatitis B vaccine. * Receipt of immune globulins, blood or blood-derived products since birth. * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth. * Family history of congenital or hereditary immunodeficiency until the immune competence of the potential vaccine recipient was demonstrated. * Individuals with blood dyscrasias, leukemia, lymphoma of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. * Individuals with active tuberculosis. * History of any Neisseria meningitidis infection, confirmed either clinically, serologically, or microbiologically. * History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, hepatitis A, measles, mumps, rubella, varicella, Haemophilus influenzae type b, Streptococcus pneumoniae, and /or rotavirus infection/disease. * At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease). * History of intussusception. * History of any neurologic disorders, including seizures and progressive neurologic disorders. * History of Guillain-Barré syndrome. * Known systemic hypersensitivity to any of the vaccine components or to latex, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances, including neomycin, gelatin, and yeast . * Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the Investigator's opinion. * Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator's opinion. * Chronic illness (including, but not limited to, cardiac disorders, congenital heart disease, chronic lung disease, renal disorders, auto-immune disorders, diabetes, psychomotor diseases, and known congenital or genetic diseases) that in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion. * Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives. * Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature \>= 38 degree Celsius \[\>= 100.4-degree Fahrenheit\]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided. * Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | Within 30 minutes post-any vaccination | An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Immediate adverse events are unsolicited systemic adverse events occurring in the 30 minutes after injection. Reported AEs for each arm were presented as pre-specified in protocol. |
| Number of Participants With Solicited Injection Site Reactions | Within 7 days post any vaccination | A solicited reaction was an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited injection site reactions included Injection site tenderness, Injection site erythema, and Injection site swelling and were planned to be collected and reported for each vaccine separately; and not planned to be collected for Rotavirus vaccine as the vaccine was administered orally, and no injection site reactions were expected to occur. Reported AEs for each arm were presented as pre-specified in protocol. |
| Number of Participants With Solicited Systemic Reactions | Within 7 days post-any vaccination | A solicited reaction was an expected AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol. |
| Number of Participants With Unsolicited Adverse Events | Within 30 days post any vaccination | An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious adverse events (SAEs) and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol. |
| Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs) | From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months) | A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. Reported AEs for each arm were presented as pre-specified in protocol. |
| Number of Participants With Medically Attended Adverse Event (MAAEs) | From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months) | A MAAE was defined as a new onset of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a health care provider's office or Emergency Department. Reported AEs for each arm were presented as pre-specified in protocol. |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
Study was conducted at 75 sites in Puerto Rico and United States from 17 September 2018 to 16 March 2023.
Pre-assignment details
A total of 2797 participants were enrolled and randomized in the study.
Participants by arm
| Arm | Count |
|---|---|
| Group 1: MenACYW Conjugate Vaccine Healthy infants aged \>= 42 to \<= 89 days (at the time of enrollment) received MenACYW Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age. | 2,099 |
| Group 2 MENVEO® Healthy infants aged \>= 42 to \<= 89 days (at the time of enrollment) received MENVEO® Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age. | 698 |
| Total | 2,797 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 11 | 1 |
| Overall Study | Lost to Follow-up | 102 | 19 |
| Overall Study | Protocol Violation | 25 | 11 |
| Overall Study | Withdrawal by Parent/Guardian | 162 | 56 |
Baseline characteristics
| Characteristic | Group 2 MENVEO® | Total | Group 1: MenACYW Conjugate Vaccine |
|---|---|---|---|
| Age, Continuous | 64.9 days STANDARD_DEVIATION 6.77 | 64.7 days STANDARD_DEVIATION 6.67 | 64.7 days STANDARD_DEVIATION 6.63 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 8 Participants | 8 Participants |
| Race (NIH/OMB) Asian | 12 Participants | 40 Participants | 28 Participants |
| Race (NIH/OMB) Black or African American | 67 Participants | 277 Participants | 210 Participants |
| Race (NIH/OMB) More than one race | 31 Participants | 133 Participants | 102 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 5 Participants | 15 Participants | 10 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 25 Participants | 22 Participants |
| Race (NIH/OMB) White | 580 Participants | 2299 Participants | 1719 Participants |
| Sex: Female, Male Female | 336 Participants | 1334 Participants | 998 Participants |
| Sex: Female, Male Male | 362 Participants | 1463 Participants | 1101 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 2,080 | 0 / 697 |
| other Total, other adverse events | 1,889 / 2,080 | 642 / 697 |
| serious Total, serious adverse events | 108 / 2,080 | 21 / 697 |
Outcome results
Primary
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Immediate adverse events are unsolicited systemic adverse events occurring in the 30 minutes after injection. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: Within 30 minutes post-any vaccination
Population: Analysis was performed on SafAS that included all participants who had received at least one dose of the study vaccines and had any safety data available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 7 Participants |
| Group 2: MENVEO® | Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 2 Participants |
Primary
Number of Participants With Medically Attended Adverse Event (MAAEs)
A MAAE was defined as a new onset of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a health care provider's office or Emergency Department. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)
Population: Analysis was performed on SafAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Medically Attended Adverse Event (MAAEs) | 1581 Participants |
| Group 2: MENVEO® | Number of Participants With Medically Attended Adverse Event (MAAEs) | 526 Participants |
Primary
Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)
Population: Analysis was performed on SafAS.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs) | SAE | 108 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs) | AESI | 19 Participants |
| Group 2: MENVEO® | Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs) | SAE | 21 Participants |
| Group 2: MENVEO® | Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs) | AESI | 1 Participants |
Primary
Number of Participants With Solicited Injection Site Reactions
A solicited reaction was an expected adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited injection site reactions included Injection site tenderness, Injection site erythema, and Injection site swelling and were planned to be collected and reported for each vaccine separately; and not planned to be collected for Rotavirus vaccine as the vaccine was administered orally, and no injection site reactions were expected to occur. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: Within 7 days post any vaccination
Population: Analysis was performed on SafAS. Here, 'Overall number of participants analyzed' = participants with available data for this outcome measure and 'Number analyzed' = participants with available data for each specified category.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | PENTACEL: Injection site Erythema | 770 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | ENGERIX-B: Injection site Tenderness | 1199 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | MenACYW or MENVEO: Injection site Swelling | 557 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | ENGERIX-B: Injection site Erythema | 539 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | PENTACEL: Injection site Swelling | 562 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | ENGERIX-B: Injection site Swelling | 347 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | MenACYW or MENVEO: Injection site Erythema | 826 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | M-M-R II: Injection site Tenderness | 786 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | M-M-R II: Injection site Erythema | 409 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | PREVNAR 13: Injection site Tenderness | 1464 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | M-M-R II: Injection site Swelling | 221 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | PENTACEL: Injection site Tenderness | 1388 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | VARIVAX: Injection site Tenderness | 724 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | PREVNAR 13: Injection site Erythema | 889 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | VARIVAX: Injection site Erythema | 364 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | MenACYW or MENVEO: Injection site Tenderness | 1501 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | VARIVAX: Injection site Swelling | 208 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Injection Site Reactions | PREVNAR 13: Injection site Swelling | 656 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | VARIVAX: Injection site Swelling | 70 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | MenACYW or MENVEO: Injection site Tenderness | 499 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | MenACYW or MENVEO: Injection site Erythema | 257 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | MenACYW or MENVEO: Injection site Swelling | 170 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | PENTACEL: Injection site Tenderness | 456 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | PENTACEL: Injection site Erythema | 255 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | PENTACEL: Injection site Swelling | 178 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | PREVNAR 13: Injection site Tenderness | 496 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | PREVNAR 13: Injection site Erythema | 298 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | PREVNAR 13: Injection site Swelling | 206 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | ENGERIX-B: Injection site Tenderness | 395 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | ENGERIX-B: Injection site Erythema | 192 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | ENGERIX-B: Injection site Swelling | 115 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | M-M-R II: Injection site Erythema | 130 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | M-M-R II: Injection site Swelling | 71 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | VARIVAX: Injection site Tenderness | 252 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | VARIVAX: Injection site Erythema | 129 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Injection Site Reactions | M-M-R II: Injection site Tenderness | 268 Participants |
Primary
Number of Participants With Solicited Systemic Reactions
A solicited reaction was an expected AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: Within 7 days post-any vaccination
Population: Analysis was performed on SafAS. Here, 'Overall number of participants analyzed' = participants with available data for this outcome measure and 'Number analyzed' = participants with available data for each specified category.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Systemic Reactions | Fever | 724 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Systemic Reactions | Vomiting | 542 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Systemic Reactions | Crying abnormal | 1437 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Systemic Reactions | Drowsiness | 1430 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Systemic Reactions | Appetite lost | 1015 Participants |
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Solicited Systemic Reactions | Irritability | 1604 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Systemic Reactions | Appetite lost | 350 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Systemic Reactions | Fever | 219 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Systemic Reactions | Drowsiness | 475 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Systemic Reactions | Vomiting | 163 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Systemic Reactions | Irritability | 536 Participants |
| Group 2: MENVEO® | Number of Participants With Solicited Systemic Reactions | Crying abnormal | 478 Participants |
Primary
Number of Participants With Unsolicited Adverse Events
An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious adverse events (SAEs) and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: Within 30 days post any vaccination
Population: Analysis was performed on SafAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | Number of Participants With Unsolicited Adverse Events | 1352 Participants |
| Group 2: MENVEO® | Number of Participants With Unsolicited Adverse Events | 437 Participants |